Child vaccination rates in the United States fell during the COVID-19 pandemic as many children skipped doctors appointments and states eased vaccine requirements during remote learning, according to a government study released on April 21.

The Biden administration wants to expand a federal COVID-19 tracking system created during the pandemic to provide a more detailed view of how respiratory and other infectious diseases are affecting patients and hospital resources, according to a draft of proposed rules reviewed by Reuters.

Janssen Pharmaceutical’s experimental vaccine for a respiratory syncytial virus (RSV) demonstrated an 80 percent efficacy level in adults over the age of 65 years.

Covid-19 probably can be eradicated globally, just like polio, according to research just published in BMJ Global Health. That assumes, however, that a high rate of vaccination occurs globally and that there is a quick response to emerging variants.

After the July 4 holiday, the U.S. Food and Drug Administration has several items on the regulatory agency’s immediate calendar, including a couple target action dates and an advisory committee hearing.

Infectious disease experts are weighing the need for booster shots of the Pfizer/BioNTech or Moderna mRNA-based vaccines for Americans who received Johnson & Johnson’s one-dose vaccine due to the increasing prevalence of the more contagious Delta coronavirus variant.

Lifebit Biotech Ltd. announced the beginning of a long-term partnership with Boehringer Ingelheim to utilize Natural Language Processing (NLP) and Artificial Intelligence (AI) for the detection and early reporting of global disease outbreaks using real-world data harvested from scientific publications and other open sources.

Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.

Affinivax Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, announced the closing of a $226 million Series C financing.

The world is caught in a perfect storm of rising rates of chronic disease, persistent infectious diseases and public health failures that have fuelled deaths in the Covid-19 pandemic, according to a major global study of human health.